Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
NUFYMCO BLA has been approved by the USFDA
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
